Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer
Lyra Therapeutics, Inc. (LYRA)
Company Research
Source: Business Wire
Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companiesExtensive experience in private and public equity financings with more than $1 billion raised CAMBRIDGE, Mass.--(BUSINESS WIRE)--Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies. He has previously served in CFO roles with publicly traded and privately held companies that include Homology Medicines, Ocular Therapeutix, OmniGuide, NeuroMetrix, and Synarc. Smith also serves as a board member and Audit Committee Chair for Lyra Therapeutics (Nasdaq
Show less
Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYRA alerts
High impacting Lyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LYRA
News
- Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisGlobeNewswire
- Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsGlobeNewswire
LYRA
Sec Filings
- 12/16/24 - Form SC
- 12/13/24 - Form 8-K
- 12/11/24 - Form 4
- LYRA's page on the SEC website